title: Precision 're'arming of CD33 antibodies.
abstract: In this issue of Blood, Kung Sutherland et al report on the preclinical activity of SGN-CD33A, a humanized anti-CD33 antibody conjugated to a pyrrolobenzodiazepine (PBD) dimer via a protease-cleavable linker, against acute myeloid leukemia (AML) cells in vitro and in vivo.
authors: M.D. Anderson Cancer Center.
authors: Gautam
authors: G
authors: Borthakur
mesh_terms: D000818:Animals; D061067:Antibodies, Monoclonal, Humanized / Q000737:chemistry*; D001569:Benzodiazepines / Q000737:chemistry*; D019008:Drug Resistance, Neoplasm; D006801:Humans; D018796:Immunoconjugates / Q000737:chemistry*; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D063268:Sialic Acid Binding Ig-like Lectin 3 / Q000737:chemistry*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D018796:Immunoconjugates; D063268:Sialic Acid Binding Ig-like Lectin 3; D001569:Benzodiazepines; C477390:lintuzumab